School of Medicine
Showing 441-460 of 624 Results
-
Sally Graglia
Clinical Associate Professor, Emergency Medicine
BioDr. Graglia, the youngest of four in an immigrant family, grew up in Southern California. Considering veterinary medicine, journalism, architecture, and Disney animation, Dr. Graglia ‘discovered people’ during a summer in undergrad working in Ethiopia, decided on medicine as her path forward, and has never looked back.
A UC child, she completed her undergraduate studies at UC Berkeley, medical school at UC Davis, and residency at UCSF with deviations to the Johns Hopkins Bloomberg School of Public Health for a Masters of Public Health and Massachusetts General Hospital (MGH) for fellowship in Emergency Ultrasound.
Having worked, learned, and/or taught throughout Africa, Europe and Eastern Europe, and Central and South America, her three pillars continue to be point-of-care ultrasound (POCUS), education, and global health with an unending drive to serve the underserved.
Outside of work, Dr. Graglia enjoys her growing family, yoga, hiking, being outside, and exploring - new cultures, places, and languages. -
Britni Wilcher
Affiliate, Center for Population Health Sciences
BioBritni Wilcher, PhD, is a Visiting Scholar in the Department of Health Policy at Stanford University and an applied microeconomist working at the intersection of health, labor, and gender economics. Dr. Wilcher's research focuses on the economics of health decision making and its implications for labor markets using quasi-experimental designs. Her research portfolio spans vulnerable populations and policy interventions, from evaluating teletherapy adoption patterns among 200,000+ veterans to conducting regulatory impact analyses protecting 22+ million workers nationwide. Her collaborative research products have withstood judicial review up to the Supreme Court and provided evidence-based input into policy actions. Her work has been cited in congressional testimony and the 2022 Economic Report of the President. It has been featured in federal regulations and published in peer-reviewed journals including Labour Economics, Health Economics, Value in Health, and the International Journal of Technology Assessment in Health Care.
Dr. Wilcher has worked in management consulting, government, universities, and has consulted with think tanks, foundations, the EU Commission, and a United Nations entity. She holds a PhD in Economics from American University, an MSc in International Health Care Management, Economics, and Policy from SDA Bocconi School of Management, and a BA in Economics from Spelman College. -
Laura Graham
Other Teaching Staff-Hourly, Surgery
BioI am an epidemiologist and health services researcher with nearly 20 years of experience in surgical outcomes research. My work focuses on improving healthcare delivery and outcomes for Veterans and other vulnerable populations, particularly those who are older or medically complex. Using large administrative datasets from the Veterans Health Administration (VA), I study surgical processes and outcomes to inform system-level improvements.
With postdoctoral training in health economics and implementation science, I bring expertise in causal inference methodology and artificial intelligence, particularly the use of natural language processing (NLP). I apply these methods to extract insights from unstructured clinical data and to strengthen causal analyses in complex healthcare datasets. These approaches allow me to address research questions that were previously difficult to study with standard empirical approaches.
As a collaborative leader, I have mentored junior investigators and worked across academic and industry sectors to advance health services research. My goal is to translate evidence into practice, ultimately improving the quality of surgical care for Veterans. -
Alana Lee Grajewski
Professor of Ophthalmology (Research and Clinical Trials)
Current Research and Scholarly InterestsGlobal Ophthalmology
Early Vision Screening
Remote Glaucoma Monitoring: Technology & Innovation
Virtual Reality Visual Field Technology
Pediatric Visual Impairment and Quality of Life
Pediatric Glaucoma Education & Training -
Philip Grant
BioMy research focuses on antiretroviral therapy and complications of HIV including immune reconstitution inflammatory disease, osteoporosis, and cardiovascular disease.
-
Teodor Grantcharov, MD, PhD, FACS, FRCS (Glasg)
Professor of Surgery (General Surgery)
BioDr. Teodor Grantcharov is a board-certified, fellowship-trained surgeon specializing in bariatric (weight loss) and minimally invasive surgery. He is also a clinical professor of surgery at Stanford University School of Medicine and associate chief quality officer for innovation and safety at Stanford Health Care.
As a surgeon, Dr. Grantcharov specializes in minimally invasive and bariatric surgery. He is an accomplished researcher and leader in the field of surgical innovation and patient safety. His work has made important contributions in curriculum design, assessments of competence, and impact of surgical performance on clinical outcomes. Dr. Grantcharov developed the surgical Black Box concept, designed to transform safety culture in medicine and introduce modern safety management systems in high-risk operating rooms.
Dr. Grantcharov has published more 220 articles in peer-reviewed journals and given more than 200 invited presentations in Europe and North and South America. He holds several patents and is the founder of Surgical Safety Technologies, Inc.—an academic startup that commercializes the Black Box Platform™. Dr. Grantcharov has received several prestigious honors and awards, including the Queen Elizabeth II Diamond Jubilee Medal for his contributions in clinical research and patient safety in Canada.
Dr. Grantcharov is a fellow of the American College of Surgeons. -
Dita Gratzinger
Professor of Pathology
Current Research and Scholarly InterestsI have research interests in the interaction of normal and neoplastic hematolymphoid cells with the bone marrow. lymph node and spleen microenvironment and the interactions of these compartments with immune perturbation and dysregulation.
-
Edward Graves
Professor of Radiation Oncology (Radiation Physics), and by courtesy, of Radiology
Current Research and Scholarly InterestsApplications of molecular imaging in radiation therapy, small animal image-guided conformal radiotherapy, immune responses to radiation, immunotherapy and radiotherapy combinations, image processing and analysis.
-
Dyneisha Gray
Program Administrator, Psych/Public Mental Health & Population Sciences
BioDyneisha holds a B.S. in Business Administration from California State University Bakersfield. Dyneisha brings administrative experience from her previous roles as an Executive Assistant and Operations Manager for Viva Superheroes where she coordinated company events and managed calendars.
-
Nathanael S. Gray
Krishnan-Shah Family Professor
BioNathanael Gray is the Krishnan-Shah Family Professor of Chemical and Systems Biology at Stanford, Co-Director of Cancer Drug Discovery Co-Leader of the Cancer Therapeutics Research Program, Member of Chem-H, and Program Leader for Small Molecule Drug Discovery for the Innovative Medicines Accelerator (IMA). His research utilizes the tools of synthetic chemistry, protein biochemistry, and cancer biology to discover and validate new strategies for the inhibition of anti-cancer targets. Dr. Gray’s research has had broad impact in the areas of kinase inhibitor design and in circumventing drug resistance.
Dr. Gray received his PhD in organic chemistry from the University of California at Berkeley in 1999 after receiving his BS degree with the highest honor award from the same institution in 1995. After completing his PhD, Dr. Gray was recruited to the newly established Genomics Institute of the Novartis Research Foundation (GNF) in San Diego, California. During his six year stay at GNF, Dr. Gray became the director of biological chemistry where he supervised a group of over fifty researchers integrating chemical, biological and pharmacological approaches towards the development of new experimental drugs. Some of the notable accomplishments of Dr. Gray’s team at GNF include: discovery of the first allosteric inhibitors of wild-type and mutant forms of BCR-ABL which resulted in clinical development of ABL001; discovery of the first selective inhibitors of the Anaplastic Lymphoma Kinase (ALK), an achievement that led to the development of now FDA-approved drugs such as ceritinib (LDK378) for the treatment of EML4-ALK expressing non-small cell lung cancer (NSCLC); and discovery that sphingosine-1-phosphate receptor-1 (S1P1) is the pharmacologically relevant target of the immunosuppressant drug Fingomilod (FTY720) followed by the development of Siponimod (BAF312), which is currently used for the treatment of multiple sclerosis.
In 2006, Dr. Gray returned to academia as a faculty member at the Dana Farber Cancer Institute and Harvard Medical School in Boston. There, he has established a discovery chemistry group that focuses on developing first-in-class inhibitors for newly emerging biological targets, including resistant alleles of existing targets, as well as inhibitors of well-validated targets, such as Her3 and RAS, that have previously been considered recalcitrant to small molecule drug development. Dr. Gray’s team developed covalent inhibitors of the T790M mutant of EGFR inspired the development of Osimertinib (AZD9291), now FDA approved for treatment of patients with relapsed lung cancer due to resistance to first generation EGFR inhibitors. Dr. Gray has also developed structure-based, generalized approaches for designing drugs to overcome one of the most common mechanisms of resistance observed against most kinase inhibitor drugs, mutation of the so-called "gatekeeper" residue, which has been observed in resistance to drugs targeting BCR-ABL, c-KIT and PDGFR.
In 2021, Dr. Gray joined Stanford University where he has joined the Stanford Cancer Institute, Chem-H and the Innovative Medicines Accelerator (IMA) to spur the development of prototype drugs.
These contributions have been recognized through numerous awards including the National Science Foundation’s Career award in 2007, the Damon Runyon Foundation Innovator award in 2008, the American Association for Cancer Research for Team Science in 2010 and for Outstanding Achievement in 2011 and the American Chemical Society award for Biological Chemistry in 2011, and the Nancy Lurie Marks endowed professorship in 2015 and the Paul Marks Prize in 2019, and the Hope Funds for Cancer Research in 2023.
